©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2026; 14(1): 112021
Published online Jan 6, 2026. doi: 10.12998/wjcc.v14.i1.112021
Published online Jan 6, 2026. doi: 10.12998/wjcc.v14.i1.112021
Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later
Salvatore Greco, Department of Internal Medicine, Ospedale del Delta, AUSL Ferrara, Lago
Michele Campigotto, Gastroenterology and Digestive Endoscopy Unit, Ospedale Ca’ Foncello, AULSS 2 Marca Trevigiana, Treviso 31100, Italy
Nicolò Fabbri, Unit of General Surgery, AUSL Ferrara, Lagosanto 44023, Ferrara, Italy
Co-first authors: Salvatore Greco and Michele Campigotto.
Author contributions: Greco S and Campigotto M were primarily responsible for drafting this letter; Fabbri N provided valuable suggestions and revised the letter; All authors thoroughly reviewed and endorsed the final manuscript. Greco S and Campigotto M contributed equally to this article and are the co-first authors of this manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Corresponding author: Salvatore Greco, MD, Department of Internal Medicine, Ospedale del Delta, AUSL Ferrara, Via valle Oppio 2, Lagosanto 44023, Ferrara, Italy. grcsvt@unife.it
Received: July 16, 2025
Revised: October 13, 2025
Accepted: December 16, 2025
Published online: January 6, 2026
Processing time: 173 Days and 22.2 Hours
Revised: October 13, 2025
Accepted: December 16, 2025
Published online: January 6, 2026
Processing time: 173 Days and 22.2 Hours
Core Tip
Core Tip: Discontinuation of advanced therapies in inflammatory bowel diseases remains a high-stakes decision, with relapse, immunogenicity, and long-term complications all weighing heavily. Despite updated international guidelines and emerging therapies, a personalized, closely monitored approach remains essential to ensure safe and effective treatment de-escalation in both Crohn’s disease and ulcerative colitis.